Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.

@article{Urasaki2001CharacterizationOA,
  title={Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.},
  author={Yoshimasa Urasaki and Gary S. Laco and P Pourquier and Yuji Takebayashi and Glenda Kohlhagen and Christopher Gioffre and Hong-Liang Zhang and Devasis Chatterjee and Panayotis Pantazis and Yves Pommier},
  journal={Cancer research},
  year={2001},
  volume={61 5},
  pages={
          1964-9
        }
}
In this study, we characterized the structure and function of topoisomerase I (top1) protein in the camptothecin (CPT)-resistant prostate cancer cell lines, DU-145/RC0.1 and DU-145/RC1 (RC0.1 and RC1, respectively). Both of the cell lines were previously selected by continuous exposure to 9-nitro-CPT. The RC0.1 and RC1 cells have high cross-resistance to CPT derivatives including SN-38 and topotecan, but are not cross-resistant to the non-top1 inhibitors etoposide, doxorubicin, and vincristine… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations

N. Jensen, Keli Agama, +9 authors Yves Pommier
  • Journal of experimental & clinical cancer research : CR
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Topoisomerase I inhibitors: selectivity and cellular resistance.

  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 1999
VIEW 4 EXCERPTS

Cure of leukemia.

  • Seminars in hematology
  • 1999
VIEW 3 EXCERPTS